Soliton Inc

Soliton — Investor Presentation (May 2020)

29 slides from Soliton's investor presentation, May 14, 2020

  1. Slide 1: Rapid Acoustic Pulse Technology

    Rapid Acoustic Pulse Technology (Nasdaq: SOLY) FOR INTERNAL USE ONLY. Do not distribute without permission.

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “bel

  3. Slide 3: Overview Summary

    Overview Summary Breakthrough acoustic shockwave device using novel and proprietary Rapid Acoustic Pulse (RAP) technology § Induces mechanical disruption to targeted cellular level structures and vacuoles § No cavitation, heat or collateral tissue damage or pain Platform technology § Tattoo removal

  4. Slide 4: Management and Directors

    Management and Directors All life science veterans Multiple device clearances Multiple national and international aesthetic device launches 5

  5. Slide 5: Science Advisory Board

    Science Advisory Board High profile Key Opinion Leaders Strong podium presence Respected, published researchers Also members of Allergan’s CoolSculpting Medical Advisory Board 6

  6. Slide 6: Device and Revenue Strategy

    Device and Revenue Strategy “razor and blade” recurring revenue model Sell or lease Hand piece contains Replaceable consumable consoles replaceable cartridge cartridge for one patient visit Images provided by Industrial Design firm; actual product may differ somewhat when the product is launched. Th

  7. Slide 7: Electrode Cartridge

    Electrode Cartridge § Electro-hydraulics (arc plasma in saline) utilizes 3000 volts at 3000 amps; creates shockwaves from .25 to 12 MPa @ 100 Hz § 8 patent § Electronic wave shaping enables very high families filed repetition rate; reduces unwanted frequencies that cause heat and pain § Worldwide ex

  8. Slide 8: Soliton's Rapid Acoustic Pulse

    Soliton’s Rapid Acoustic Pulse § Repetition rate and very short rise time provide microscopic mechanical disruption to targeted cellular level structures and vacuoles § High peak pressure and fast repetition rate exploit viscoelastic nature of tissue § Compressed pulses from electronic filtering and

  9. Slide 9: Acoustic ECM Disruption—Septa Disruption Time Dose Response

    OPT A Acoustic ECM Disruption—Breakthrough Septa Disruption—Time Dose Response (Source: Control—Tx#26, Pig202 (68659); Test—Tx#63, Day O, Pig 210a. R1-R3 (68659 vs 91940 vs 91939 vs 91900); Head: Omega set at higher power 2800v, 100HZ, 70ms) CONTROL – 20X 1 MIN – 20X 2 MIN – 20X 3 MIN – 20X 10

  10. Slide 10: Potential Fibrosis Treatment: Long-Term Importance

    Potential Fibrosis Treatment: Long-Term Importance What causes Fibrosis? Stiff Extracellular Fibrotic Fibroblast Matrix (“ECM”) Fibroblast Fibrosis RAP Treatment for Fibrosis Multiple Aesthetic Indications RAP Fibrotic Preventative Stiff Non-Stiff or Tissue Fibroblast ECM ECM Therapeutic Disruption

  11. Slide 11: Soliton's Pipeline

    Soliton’s Pipeline FDA Commercial GLOBAL MARKET Indication Pre-Clinical Human POC Pivotal Clearance Launch OPPORTUNITY Tattoo Removal $4.0B Cellulite Reduction $4.0B Keloid and Hypertrophic Scar Reduction $10.0B Skin Laxity Reduction $6.3B 13

  12. Slide 12: Targeted Indications

    Targeted Indications Pathway Cleared In Clinic Future Tattoo Removal Tattoo Removal Cellulite Skin Rejuvenation: Abdomen Cellulite: Skin Rejuvenation Skin Rejuvenation: General Skin Rejuv.: Knees/Elbows Fibrotic Scars Post-Surgical Keloid: Radiation Induced Fibrotic Scars Radiation Induced (Preventa

  13. Slide 13: Tattoo Removal: First Indication

    Tattoo Removal: First Indication

  14. Slide 14: Tattoo removal market prospects

    63%* are considering tattoo removal 44 million Americans 70 23% are want some form of MILLION “regretters”** tattoo removal 44 So, why isn’t this already MILLION a billion dollar business? US prospects 29% have at 240 least one tattoo MILLION *As demonstrated in our own proprietary market research c

  15. Slide 15: Laser Removal presents huge barriers

    Laser Removal (current standard of care) presents huge barriers Complete tattoo removal means repeating visits >10 times over 1 - 2 years* Timeline reduction changes industry approach *December 2012 Archives of Dermatology There is no guarantee of any outcome. Patients' individual experiences may va

  16. Slide 16: Statistically Significant Clinical Results

    Statistically Significant Clinical Results § Soliton RAP delivered 75% or greater fading in 100% of patients* after 3 office visits § Outperformed “laser-only” 100%* of the time *Results presented from the Company’s 2017 clinical trial. Fading percentages were determined by a panel of unaffiliated d

  17. Slide 17: Complete removal of treated ink after treatments

    Complete removal of Before treated ink after 3 treatments After 3 Treatments Individual results will vary. For illustrative purposes only. 19

  18. Slide 18: Cellulite Treatment: Second Potential Indication

    Cellulite Treatment: Second Potential Indication FOR INTERNAL USE ONLY. Do not distribute without permission.

  19. Slide 19: Cellulite market opportunity

    95 54 million US MILLION Total US women want to Women Population improve their cellulite (Age 15-54) $4B market by 2025.* 81 80-90% suffer MILLION 5% market share = from cellulite $200M revenue. 67%** want to do something 54 about it MILLION US prospects *Is indicated in Medical News Today November

  20. Slide 20: Competitive Landscape in Cellulite

    Competitive Landscape in Cellulite Long-term Side Patient Company Technology Noninvasive Avg Cost # Trmts Duration Effects Satisfaction Syneron Candela RF $1,600 4+ L 60% Cynosure RF & massage 6 L Solta RF $2,475 1 H 67% BTL RF & targeted pressure energy $3,100 4 L 90% Venus Concept RF & pulsed EM f

  21. Slide 21: The Soliton Approach to Cellulite

    The Soliton Approach to Cellulite Acoustic Subcision Cellulite Dimples Epidermis Dermis Fat Cells Fibrous Septa Septa contracts and becomes sclerotic holding Our device emits rapid acoustic shock wave portions of the skin with a non-flexible length of septa pulses that are transmitted through the sk

  22. Slide 22: Results: POC RAP Cellulite Trial

    Results: POC POC RAP Cellulite Trial Single-Treatment 26-Week CSS Scores IPR Average Assessment (n=3) Efficacy 5.00 § 100% correct selection of the before and 5.0 4.83 12-week post-treatment photos by all 4.67 P < 0.001 blinded reviewers 4.27 4.00 4.00 § At 26 weeks, average reduction of the 4.0 Cel

  23. Slide 23: POC Trial Patient after Single RAP Treatment

    POC Trial Patient after Single RAP Treatment Before 12-WK 26-WK

  24. Slide 24: Keloid and Hypertrophic Scar Treatment: Third Potential Indication

    Keloid and Hypertrophic Scar Treatment: Third Potential Indication (and Support for Other Fibrotic Disease Targets) FOR INTERNAL USE ONLY. Do not distribute without permission.

  25. Slide 25: Fibrotic Scar POC Trial Results

    Fibrotic Scar POC Trial Results Change in Keloid Volume Average Scar Volume Change at 6 and 12 weeks RAP V. Cryo+TAC Post Single 6 minute RAP Treatment 40 200 35 190.9 180 30 25 % Vol Change - RAP 160 20 % Vol Change - 4x Cryo+TAC VOLUME 29.6% RAP Treatment 140 15 Cryo+TAC Treatments 138.4 % Decreas

  26. Slide 26: COVID-19 Impact

    COVID-19 IMPACT Significant economic impact on the aesthetic marketplace with majority of cosmetic dermatologists shuttering their practice during stay-at-home orders Revised commercial launch timeline appropriate in this environment; plan modified to incorporate cellulite technology into initial la

  27. Slide 27: Post Covid-19 Tentative Commercialization Pathway

    Post Covid-19 Tentative Commercialization Pathway 2020 2021 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 COVID-!9 IMPACT Brand Development FDA – Device Upgrades Staffing Additions COVID-!9 IMPACT Commercial Launch Sales Force Build Cellulite FDA Clearance This schedule portrays a possible path to commerc

  28. Slide 28: Key Milestones

    Key Milestones MILESTONE ANTICIPATED TIMING FDA Clearance for Tattoo Removal May 2019 Cellulite POC study– 26-week time point May 2019 Cellulite POC 26-week Data Release in Las Vegas Aesthetics Show July 2019 Initiate Cellulite Pivotal Trial Mid 2019 Keloid Scarring POC Trial Mid 2019 FDA Clearance

  29. Slide 29: Thank you

    Thank you Rapid Acoustic Pulse Technology (Nasdaq: SOLY) FOR INTERNAL USE ONLY. Do not distribute without permission.

Soliton — Investor Presentation (May 2020) on 6ix